Severin Schwan, Roche CEO (AP Images)

Roche to read out even more da­ta on megablock­buster Ocre­vus in MS

It’s been three years since Roche hit the mar­ket with its megablock­buster MS drug Ocre­vus — but the Swiss phar­ma isn’t done build­ing on the pro­gram that CEO Sev­erin Schwan has called the most suc­cess­ful launch in the com­pa­ny’s 124-year his­to­ry.

Roche says it’s go­ing to MSVir­tu­al2020 next week­end with new ef­fi­ca­cy da­ta for the treat­ment of mul­ti­ple scle­ro­sis (MS) and neu­romyelitis op­ti­ca spec­trum dis­or­der (NMOSD) pa­tients. Plus, it’s ini­ti­at­ing a Phase II­Ib study to eval­u­ate Ocre­vus at a high­er dose for re­laps­ing and pri­ma­ry pro­gres­sive MS pa­tients, and a Phase IV CHIMES study which will fo­cus on the drug’s ef­fi­ca­cy in African Amer­i­can, His­pan­ic and Lat­inx Amer­i­can pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.